"Missing on 3 point MACE would be a bummer for sure but having an increase of 5% to 10% in each of eGFR and cognitive function could create quite a stir."

It could create a stir, but Growacet made a good point over on the other board in this post:

"I know that some have expressed the view that if BETonMACE fails to prove a statistically significant improvement in time to first occurrence of adjudication-confirmed narrowly defined MACE....some have argued that secondary endpoints around CKD and Cognition could still provide a path foward. 

Personally I don't see it....and here is why. If the trial fails on MACE, then Resverlogix is back to having to design a new trial or trials...and I suspect with CKD and Cognition they'd be starting from Phase 2, which by my read would mean adding another 2 or more likely 3 years to the possibility of comercialization of Apabetalone."

BDAZ